STOCK TITAN

Illumina Inc - ILMN STOCK NEWS

Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.

Illumina Inc (ILMN), a global leader in genomic sequencing technologies, provides critical tools advancing precision medicine and life science research. This dedicated news hub offers investors and industry professionals centralized access to official press releases, financial disclosures, and strategic updates directly from the company.

Track developments across key areas including quarterly earnings, sequencing platform innovations, and global health partnerships. Stay informed about regulatory milestones, product launches, and collaborations shaping the future of genomic analysis. Bookmark this page for unfiltered access to Illumina's latest announcements, enabling data-driven decisions in the rapidly evolving biotechnology sector.

Rhea-AI Summary

Illumina has partnered with Embark Veterinary to launch a DNA test that accurately determines dogs' ages using methylation patterns. This innovation stems from the need for dog owners to understand their pets' genetic makeup for better health management. During beta testing, 40% of users took action after discovering their dog's true age, with many seeking veterinary care. The test could improve dogs' longevity and health by providing critical insights for owners, enabling informed decisions regarding care, nutrition, and lifestyle changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary

Illumina, Inc. (NASDAQ: ILMN) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. The event will start at 3:45 PM PT and includes a Q&A session at 4:05 PM PT. Investors can access the webcast through the Investor Info section of Illumina's website, with a replay available for 30 days post-event. Illumina is a leader in DNA sequencing technology, focused on enhancing human health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
conferences
-
Rhea-AI Summary

Point32Health, parent of Harvard Pilgrim Health Care, expands a pilot offering GRAIL's Galleri multi-cancer detection test to Maine members at no cost. This initiative aims to gather real-world evidence on healthcare utilization and patient outcomes, targeting high cancer rates in Maine. The Galleri test can detect signals across over 50 cancer types with a low false positive rate. Point32Health stands out as the first U.S. commercial health plan to integrate Galleri, complementing existing cancer screenings to enhance early detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
Rhea-AI Summary

GRAIL, LLC announced findings from its CCGA study, revealing that methylation techniques demonstrated the highest cancer signal detection sensitivity at 98% specificity, outperforming other approaches. This research supports the development of the Galleri® multi-cancer early detection blood test, capable of identifying signals from over 50 cancer types. The study involved 2,800 participants and emphasized the importance of rigorous genomic measures for cancer detection. The findings will refine the Galleri test, enhancing its capability in early cancer diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
none
-
Rhea-AI Summary

Illumina, Inc. (NASDAQ: ILMN) will present at two upcoming investor conferences. The Evercore ISI HealthCONx Conference is on November 29, 2022, featuring a fireside chat at 8:20am PT. Additionally, Illumina will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, starting at 6:00am PT. Webcasts will be accessible through Illumina’s Investor Info website, with replays available for 30 days after each event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
conferences
Rhea-AI Summary

Illumina reported Q3 2022 revenue of $1.12 billion, a 1% increase year-over-year. The company incurred a GAAP diluted loss per share of $(24.26), driven by a $3.91 billion goodwill impairment related to the GRAIL segment. Non-GAAP diluted EPS stood at $0.34, down from $1.45 in Q3 2021. For fiscal 2022, the company expects overall revenue growth to be flat to 1% higher and anticipates a GAAP diluted loss per share between $(26.56) and $(26.41). Innovation continues with 50 orders for the new NovaSeq X.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
-
Rhea-AI Summary

Anavasi Diagnostics, a medical technology firm, has elected three new board members: Bryan Crane, PhD, from Illumina, Arthur Kirsch from Liquidia Corp, and David Vied from Cyanotech Corporation. This expansion aims to leverage their extensive industry experience to enhance Anavasi's growth as it progresses through clinical trials and product development. Nelson Patterson, CEO, expressed optimism about the fresh perspectives these members will bring. Anavasi has secured $6 million in seed funding and is currently in a $20 million Series A fundraising round.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
management
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) and Illumina, Inc. (NASDAQ: ILMN) announced a partnership to enhance research capabilities with the co-branded Twist® for Illumina® Exome 2.0 Plus panel. Twist will manufacture the panel, which features high uniformity, low off-target rates, and is designed for Illumina sequencers. This collaboration aims to provide a market-leading exome panel, facilitating improved customer access to advanced genomic solutions. Both companies are recognized as leaders in genomics and next-generation sequencing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
partnership
Rhea-AI Summary

Illumina (NASDAQ: ILMN) launched the Urinary Pathogen Infectious Disease/Antimicrobial Resistance (ID/AMR) Panel (UPIP) on Nov. 1, 2022, utilizing precision metagenomics to identify over 170 pathogens and 3700 AMR markers within 48 hours. This panel addresses urgent public health needs, as urinary tract infections (UTIs) lead to 10 million office visits and 1 million hospitalizations annually in the U.S. UPIP enhances infection detection without traditional culture methods, positioning Illumina as a leader in combating antimicrobial resistance and supporting global health preparedness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
none
Illumina Inc

Nasdaq:ILMN

ILMN Rankings

ILMN Stock Data

11.27B
157.95M
0.3%
105.88%
4.11%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SAN DIEGO